trial

Ascertaining Diagnosis Classification With Elicited Speech

NCTId NCT05601063
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 255 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2022-09-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
255 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2020-10-01
Primary completion
2022-09-01
Eligibility
ALL · 14 Years · 50 Years

Interventions & indications

Drugs
Winterlight Speech Assessment

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
Winterlight LabsCollaborator

Investigators

1
Sunny X Tang, MDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
255
Phase
NA
Primary Completion Date
2022-09-01
Status
COMPLETED
relationships
The graph out of here
drug
Winterlight Speech Assessment
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
Winterlight Labs
company
indication
Depressive Disorder
indication
Personality Disorders
indication
Attention Deficit Disorder with Hyperactivity
indication
investigator
Sunny X Tang, MD
person